UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 204

Sortiert nach

Immune-checkpoint inhibitors: long-term implications of toxicity

Nature reviews. Clinical oncology, 2022-04, Vol.19 (4), p.254-267

2022

Link zum Volltext

Verfügbarkeit prüfen

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Nature reviews. Clinical oncology, 2016-11, Vol.13 (11), p.674-690

2016

Link zum Volltext

Verfügbarkeit prüfen

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

Clinical cancer research, 2019-04, Vol.25 (8), p.2392-2402

2019

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response

Frontiers in immunology, 2022-02, Vol.13, p.844866-844866

2022

Link zum Volltext

Verfügbarkeit prüfen

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

Journal of clinical oncology, 2011-11, Vol.29 (33), p.4452-4461

2011

Link zum Volltext

Verfügbarkeit prüfen

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

Nature nanotechnology, 2019-03, Vol.14 (3), p.269-278

2019

Link zum Volltext

Verfügbarkeit prüfen

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Nature communications, 2021-11, Vol.12 (1), p.6276-6276, Article 6276

2021

Link zum Volltext

Verfügbarkeit prüfen

Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration

Journal of controlled release, 2021-02, Vol.330, p.1118-1129

2021

Link zum Volltext

Verfügbarkeit prüfen

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy

The Journal of clinical investigation, 2020-05, Vol.130 (5), p.2570-2586

2020

Link zum Volltext

Verfügbarkeit prüfen

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

Nature communications, 2018-01, Vol.9 (1), p.248-11, Article 248

2018

Link zum Volltext

Verfügbarkeit prüfen

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.134-9, Article 134

2019

Link zum Volltext

Verfügbarkeit prüfen

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Breast cancer research : BCR, 2014-08, Vol.16 (4), p.406-406, Article 406

2014

Link zum Volltext

Verfügbarkeit prüfen

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Cancer research (Chicago, Ill.), 2016-01, Vol.76 (2), p.305-318

2016

Link zum Volltext

Verfügbarkeit prüfen

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Proceedings of the National Academy of Sciences - PNAS, 2013-08, Vol.110 (35), p.14372-14377

2013

Link zum Volltext

Verfügbarkeit prüfen

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma

Journal for immunotherapy of cancer, 2020-03, Vol.8 (1), p.e000282

2020

Link zum Volltext

Verfügbarkeit prüfen

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

The Journal of clinical investigation, 2014-11, Vol.124 (11), p.4737-4752

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer

Scientific reports, 2018-03, Vol.8 (1), p.4899-9, Article 4899

2018

Link zum Volltext

Verfügbarkeit prüfen

Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms

Breast cancer research : BCR, 2021-10, Vol.23 (1), p.96-96, Article 96

2021

Link zum Volltext

Verfügbarkeit prüfen

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Nature communications, 2017-09, Vol.8 (1), p.606-18, Article 606

2017

Link zum Volltext

Verfügbarkeit prüfen

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

Cancer discovery, 2018-02, Vol.8 (2), p.143-145

2018

Link zum Volltext

Verfügbarkeit prüfen

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Nature medicine, 2012-07, Vol.18 (7), p.1052-1059

2012

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Cancer research (Chicago, Ill.), 2011-03, Vol.71 (5), p.1871-1882

2011

Link zum Volltext

Verfügbarkeit prüfen

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies

Scientific reports, 2017-05, Vol.7 (1), p.1526-11, Article 1526

2017

Link zum Volltext

Verfügbarkeit prüfen

Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer

Oncoimmunology, 2020-01, Vol.9 (1), p.1758547-1758547

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(192)
Mit Volltextzugriff
(189)

Publikationsform

Sprache

Englisch
(204)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Immune-checkpoint inhibitors: long-term implications of toxicity

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer

Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies

Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer

Suchergebnisse filtern